Nano-Carrier Mediated Co-delivery of Methyl Prednisolone and Minocycline for Improved Post Traumatic Spinal Cord Injury Conditions in Rats.

Related Articles

Nano-Carrier Mediated Co-delivery of Methyl Prednisolone and Minocycline for Improved Post Traumatic Spinal Cord Injury Conditions in Rats.

Drug Dev Ind Pharm. 2017 Mar 10;:1-24

Authors: Wu XF, Zhou ZH

Abstract
OBJECTIVE: To investigate the fate of albumin coupled nanoparticulate system over non-targeted drug carrier in the treatment of hemisectioned spinal cord injury (SCI).
SIGNIFICANCE: Targeted delivery of methyl prednisolone (MP) and minocycline (MC) portrayed improved therapeutic efficacy as compared to non-targeted nanoparticles.
METHODS: Albumin coupled, Chitosan stabilized, and cationic nanoparticles (albumin-MP + MC-NPS) of poly-(lactide-co-glycolic acid) were prepared using the emulsion solvent evaporation method. Prepared nanoparticles were characterized for drug entrapment efficiency, particle size, poly-dispersity index (PDI), zeta potential, and morphological characteristics. Their evaluation was done based on pharmaceutical, toxicological and pharmacological parameters.
RESULTS AND DISCUSSION: In vitro release of MP+MC from albumin-MP+MC-NPS and MP+MC-NPS was observed to be very controlled for the period of eight days. Cell viability study portrayed non-toxic nature of the developed nanoparticles. Albumin-MP+MC-NPS showed prominent anti-inflammatory potential as compared to non-targeted nanoparticles (MP+MC-NPS) when studied in LPS induced inflamed astrocytes. Albumin-MP+MC-NPS reduced lesional volume and improved behavioral outcomes significantly in rats with SCI (hemisectioned injury model) when compared with that of MP+MC-NPS.
CONCLUSIONS: Albumin coupled nanoparticles carrier offered an effective method of SCI treatment following safe co-administration of MP and MC. The in vitro and in vivo effectiveness of MP+MC was improved tremendously when compared with the effectiveness showed by MP+MC-NPS. That could be attributed to the site specific, controlled release of MP+MC to the inflammatory site.

PMID: 28279078 [PubMed - as supplied by publisher]

http://ift.tt/2lNtR2y